aqw051
Small moleculeexperimental
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started May 1, 2006 (NCT00418002)
Timeline
Indications
Mechanism of action
- Neuronal acetylcholine receptor protein alpha-7 subunitPARTIAL AGONIST
CHRNA7 partial agonist
Alpha-7 nicotinic receptor: consists entirely of a7 subunits (pentamere) CNS-type.
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(-c2ccc(OC3CN4CCC3CC4)cn2)cc1- Mol. weight
- 294.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545232 ↗
Also known as
- 3-(6-p-tolylpyridin-3-yloxy)-1-azabicyclo(2.2.2)octane
- aqw051
- aqw051
- aqw051
- aqw051
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07221578 | Phase 3 | Sep 22, 2025 | Vanda Pharmaceuticals |
| NCT04800237 | Phase 2 | Feb 23, 2021 | Vanda Pharmaceuticals |
| NCT01730768 | Phase 2 | Sep 1, 2012 | Novartis |
| NCT01474421 | Phase 2 | Sep 15, 2011 | Novartis |
| NCT01163227 | Phase 2 | May 1, 2010 | Novartis |
| NCT00825539 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2009 | Novartis |
| NCT00582855 | Phase 2 | Dec 1, 2007 | Novartis |
| NCT00409500 | Phase 1 | Oct 1, 2006 | Novartis |
| NCT00418002 | Phase 1 | May 1, 2006 | Novartis |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 7 | 7 | 2 | 2006 |
| Vanda Pharmaceuticals | For profit | 2 | 2 | 2 | 2021 |
2 organizations
Page 1 / 1